Swiss pharmaceutical giants fear Trump’s return

Faced with fear of possible reprisals by the Trump administration, “hope alone is not enough for Big Pharma,” notes “SonntagsBlick”. Thus, Roche and Novartis, which invest billions in research across the Atlantic, also appear in the top 30 companies most active in lobbying in Washington: since 2015, they have devoted 8.4 and 6.5 million dollars respectively. per year on average, reports the NGO Open Secrets, which tracks money in American politics and its effects on elections and public policies.